IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, May 2025
Impact Factor: 7.67

A Review on Probiotics and Their Use in the Treatment of Various Diseases

Sarika Joga[1], Sreekanth Madathala[2], Pothula Sreeja[3], Puram Ruchitha[4]
Assistant Professor, Department of Pharmacology[1]
Professor, HOD of Pharm D[2]
Students, Department of Pharmacology[3,4]
Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Hyderabad, India

Abstract: *Probiotics are live microorganisms that provide health benefits when consumed in adequate amounts, primarily by modulating the host's microbiota and immune responses. Traditionally recognized for their role in maintaining gut health, probiotics are now gaining attention for their therapeutic potential in a variety of diseases, including gastrointestinal disorders, metabolic syndromes, allergic conditions, urogenital infections, neurological diseases, and even as adjuncts in cancer therapy. This review highlights the mechanisms through which probiotics exert their effects—such as enhancing intestinal barrier function, competitive inhibition of pathogens, and immunomodulation. Furthermore, it explores specific probiotic strains and their efficacy in clinical settings, supported by current scientific evidence. Despite promising outcomes, the field faces challenges regarding strain specificity, regulatory standards, and long-term safety. Future research directions include the development of personalized probiotics, synbiotics, and postbiotics to enhance therapeutic outcomes*

Keywords: Probiotics, Gut Microbiota, Gastrointestinal Diseases, Immune Modulation, Metabolic Disorders, Psychobiotics, Synbiotics, Postbiotics, Clinical Applications, Microbial Therapy.

I. INTRODUCTION

Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host. Most commonly consisting of bacterial strains from the genera Lactobacillus, Bifidobacterium, and Saccharomyces, probiotics are primarily known for their roles in gut health. However, emerging research highlights their therapeutic potential in a wide array of diseases beyond the gastrointestinal (GI) tract, including metabolic, immunological, and psychological disorders.

II. MECHANISMS OF ACTION

Probiotics exhibit their effects through several mechanisms:

- Restoration of gut microbiota balance
- Enhancement of epithelial barrier function
- Production of antimicrobial substances (e.g., bacteriocins)
- Modulation of the immune system
- Reduction of inflammation by downregulating pro-inflammatory cytokines
- Competitive exclusion of pathogens by occupying adhesion sites

Copyright to IJARSCT
www.ijarsct.co.in
DOI: 10.48175/IJARSCT-26275

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, May 2025
Impact Factor: 7.67



Fig 1: PROBIOTIC USES

III. THERAPEUTIC APPLICATIONS OF PROBIOTICS

3.1 Gastrointestinal Diseases

a. Irritable Bowel Syndrome (IBS)

- Probiotic strains: Lactobacillus plantarum, Bifidobacterium infantis
- Mechanism: Modulate gut motility, reduce bloating, and normalize stool frequency.
- Evidence: Meta-analyses have shown significant symptom relief in IBS patients using multispecies probiotics.

b. Inflammatory Bowel Disease (IBD)

- Probiotic strains: Escherichia coli Nissle 1917, VSL#3 (a probiotic mixture)
- Use: Maintaining remission in ulcerative colitis; less effective in Crohn's disease.
- Mechanism: Anti-inflammatory effects and immune modulation.

c. Antibiotic-Associated Diarrhea (AAD)

- Probiotic strains: Lactobacillus rhamnosus GG, Saccharomyces boulardii
- Use: Preventing diarrhea following antibiotic use, especially in children.
- Evidence: Strong, with consistent results across multiple RCTs.

3.2 Metabolic Disorders

a. Obesity and Type 2 Diabetes

- Probiotic strains: Lactobacillus gasseri, Bifidobacterium breve
- Mechanism: Alteration of gut microbiota to favor lean phenotype, improved insulin sensitivity, reduction of systemic inflammation.

Copyright to IJARSCT
www.ijarsct.co.in
DOI: 10.48175/IJARSCT-26275

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, May 2025
Impact Factor: 7.67

- Evidence: Promising but mixed; more research is needed on strain specificity and dosage.

b. Non-Alcoholic Fatty Liver Disease (NAFLD)

- Use: Improvement in liver enzymes and lipid profiles.
- Mechanism: Reduction of endotoxemia and oxidative stress.

3.3 Allergic Disorders

a. Atopic Dermatitis

- Probiotic strains: Lactobacillus rhamnosus GG
- Use: Preventive use in infants and symptom reduction in children.
- Mechanism: Modulation of immune response (Th1/Th2 balance).
- Evidence: Moderate effectiveness; early-life administration may be key.

b. Allergic Rhinitis and Asthma

- Evidence: Mixed results, with some improvement in symptom scores but limited impact on clinical outcomes.

3.4 Urogenital Infections

- Probiotic strains: Lactobacillus crispatus, L. rhamnosus GR-1
- Use: Treatment and prevention of bacterial vaginosis, urinary tract infections (UTIs)
- Mechanism: Maintenance of acidic vaginal pH and inhibition of pathogens.
- Evidence: Supportive but varies by strain and delivery method (oral vs vaginal).

3.5 Neurological and Psychological Disorders (Psychobiotics)

- Probiotic strains: Lactobacillus helveticus, Bifidobacterium longum
- Use: Reduction in anxiety, depression, and cognitive decline.
- Mechanism: Gut-brain axis modulation via neurotransmitter production (e.g., GABA, serotonin), anti-inflammatory effects.
- Evidence: Emerging field; preliminary trials show promise.

3.6 Cancer

- Use: Support during chemotherapy (reduce mucositis, diarrhea), enhance immune surveillance.
- Mechanism: Regulation of immune checkpoints, reduction in pro-carcinogenic bacterial metabolites.
- Evidence: Early-stage clinical trials suggest benefit, particularly in colorectal cancer.

IV. SAFETY AND LIMITATIONS

While probiotics are generally safe for healthy individuals, there are some risks:

• Immunocompromised patients may be at risk of bacteremia or fungemia.
• Strain-specific effects mean that not all probiotics are beneficial for all conditions.
• Regulatory variability: Probiotic supplements are often not subject to the same scrutiny as pharmaceuticals.
• Transient colonization: Many probiotics do not permanently colonize the gut, requiring continuous intake.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, May 2025
Impact Factor: 7.67



Fig 2: PROBIOTIC APPROCHES

V. FUTURE DIRECTIONS AND RESEARCH NEEDS

- Personalized probiotics based on individual microbiomes.
- Synbiotics (combination of probiotics and prebiotics) for enhanced efficacy.
- Postbiotics (metabolites produced by probiotics) as potential therapeutic agents.
- High-quality RCTs to better define strain-specific effects, dosing, and long-term safety.

VI. CONCLUSION

Probiotics represent a promising adjunct or alternative in the treatment of a variety of diseases, particularly those involving the gut and immune system. Their safety profile and wide-ranging mechanisms make them a valuable tool in preventive and therapeutic medicine. However, robust, high-quality, and long-term studies are still needed to confirm efficacy across different populations and conditions